DRL-Header DRL-Header

X

Find FDA Investigational New Drug (IND) Submissions for Musculoskeletal in UNITED STATES

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): Antibody-Oligonucleotide Conjugates

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: RTW Investments

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing May 26, 2020

            Details:

            The funds will enable Avidity to advance Company's growing proprietary portfolio of multiple programs, including Its AOC treatment of myotonic dystrophy type I, to treat serious muscle disorder.